Comparison of the Applicability of Two Prognostic Scoring Systems In Patients with Fulminant Hepatic Failure by Choi, Won-Choong et al.
The  Korean  Journal  of  Internal  Medicine  :  22:93-100,  2007
Comparison of the Applicability of Two Prognostic 
Scoring Systems In Patients 
with Fulminant Hepatic Failure
Won-Choong Choi, M.D., Walid C. Arnaout, M.D.
2, Federico G. Villamil, M.D.
2,
Achilles A. Demetriou, M.D., Ph.D.
2  and John M. Vierling, M.D.
2 
Department  of  Internal  Medicine,  Sanggye-Paik  Hospital,  Inje  University,  College  of  Medicine  Seoul,  Korea;
The  Center  for  Liver  Diseases  and  Transplantation  and 
The  Burns  and  Allen  Research  Institute  Cedars-Sinai  Medical  Center  Los  Angeles,  USA
2
Background  :  Distinguishing  those  patients  with  fulminant  hepatic  failure  (FHF)  and  who  require  transplantation  from 
those  FHF  patients  who  will  survive  with  receiving  only  intensive  medical  care  remains  problematic,  and  this  distinction 
is  important  because  of  the  chronic  shortage  of  donor  livers. 
Methods  :  To  assess  the  applicability  of  two  prognostic  scoring  systems,  referred  to  as  the  London  and  Clichy 
criteria,  we  compared  using  both  systems,  at  the  time  of  admission,  for  43  FHF  patients  (15  M/28  F;  age:  3716  yrs). 
Acetaminophen  (ACM)  was  the  etiology  for  16  patients,  while  the  remaining  27  had  other  etiologies.  All  the  patients 
received  intensive  care,  and  18  (8  ACM/10  non-ACM)  had  investigational  BAL  support. 
Results  :  For  the  ACM  toxicity,  neither  the  London  nor  the  Clichy  criteria  exhibited  acceptable  sensitivity  (71  vs  86%, 
respectively),  specificity  (78  vs  56%,  respectively),  a  positive  predictive  value  (71  vs  60%,  respectively),  a  negative 
predictive  value  (78  vs  83%,  respectively)  or  predictive  accuracy  (75  vs  69%,  respectively)  to  predict  patient  survival 
without  transplantation.  In  contrast,  applying  the  London  and  Clichy  criteria  to  the  FHF  patients  with  non-ACM 
etiologies  showed  a  sensitivity  of  96  vs  80%,  respectively,  a  specificity  of  100  vs  100%,  respectively,  a  positive 
predictive  value  of  100  vs  100%,,  respectively  a  negative  predictive  value  of  67  vs  29%,  respectively  and  a  predictive 
accuracy  of  96%  vs  82%,  respectively. 
Conclusions  :  Overall,  the  London  criteria  more  accurately  predicted  the  need  for  transplantation,  and  neither  the 
London  criteria  nor  the  Clichy  prognostic  criteria  accurately  predicted  the  outcome  of  those  patients  who  suffered  with 
FHF  due  to  ACM.  BAL  support  may  have  contributed  to  the  survival  of  the  patients  with  ACM  toxicity  and  who  didn't 
undergo  transplantation,  and  this  survival  exceeded  the  predictions  of  both  prognostic  systems.  Additional  multicenter 
studies  should  be  conducted  to  refine  these  prognostic  scoring  systems,  and  this  will  help  physicians  rapidly  identify 
those  FHF  patients  who  can  survive  without  undergoing  liver  transplantation. 
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INTRODUCTION 
Fulminant  hepatic  failure  (FHF)  was  originally  defined  by  Trey 
and  Davidson  in  1970  as  the  occurrence  of  hepatic  encephalo-
pathy  within  8  weeks  of  the  onset  of  acute  liver  disease  in  the 
absence  of  chronic  liver  disease
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Etiology Gender/Age Encephalopathy  on  admission BAL Prognostic  Criteria Outcome
I‐II:  (-)      III‐IV:  (+) London Clichy LT No  LT
Acetaminophen
1 F/21 (+) (+) TP (+) TP D
2 F/47 (+) (+) (-) TN (-) TN S
3 F/18 (+) (+) (+) TP (+) TP S
4 F/48 (-) (-) TN (-) TN S
5 F/34 (-) (+) (-) TN (-) TN S
6 F/37 (-) (+) (+) FP (-) TN S
7 F/27 (+) (+) (-) TN (+) FP S
8 M/32 (-) (-) FN (+) TP D
9 F/18 (-) (-) TN (+) FP S
10 F/26 (+) (+) (-) FN (+) TP D
11 F/52 (+) (+) TP (-) FN D
12 F/50 (+) (+) TP (+) TP S
13 F/75 (-) (-) TN (-) TN S
14 F/18 (+) (+) (+) TP (+) TP S
15 M/35 (-) (+) (-) TN (+) FP S
16 F/31 (-) (-) TN (+) FP S
Non‐acetaminophen
17 indeterminate F/26 (+) (+) (+) TP (+) TP S
18 indeterminate F/36 (-) (-) TN (-) TN S
19 indeterminate F/23 (+) (+) TP (-) FN D
20 indeterminate M/34 (+) (+) TP (+) TP S
21 indeterminate M/10 (+) (+) TP (+) TP S
22 indeterminate M/24 (+) (+) TP (+) TP S
23 indeterminate F/28 (+) (+) TP (+) TP D
24 indeterminate F/31 (+) (+) (+) TP (-) FN S
25 indeterminate M/51 (+) (+) (+) TP (+) TP S
26 indeterminate F/31 (-) (+) TP (-) FN S
27 indeterminate F/52 (+) (+) (+) TP (+) TP S
28 Drug F/35 (+) (+) TP (+) TP S
29 Drug M/16 (+) (+) TP (+) TP D
30 Drug M/48 (+) (+) (+) TP (+) TP S
31 Drug F/52 (+) (+) (+) TP (+) TP D
32 Drug M/26 (+) (+) (+) TP (+) TP D
33 Hepatitis  B F/56 (+) (+) (+) TP (+) TP S
34 Hepatitis  B M/36 (+) (+) TP (+) TP D
35 Hepatitis  B M/44 (+) (+) TP (-) FN S
36 Hepatitis  A M/50 (+) (+) TP (+) TP S
37 Hepatitis  A M/69 (-) (+) TP (+) TP S
38 ischemia M/71 (+) (+) TP (+) TP D
39 ischemia F/71 (-) (-) TN (-) TN S
40 Wilson F/21 (+) (+) TP (+) TP D
41 autoimmune F/38 (+) (+) (+) TP (+) TP S
42 heat  stroke M/58 (+) (+) (+) TP (-) FN D
43 HELLP F/34 (+) (-) FN (+) TP S
BAL,  bioartifial  liver;  D,  death;  S,  survivor;  LT,  liver  transplantation;  HELLP,  hemolysis,  elevated  liver  enzymes  and  low  platelet  syndrome; 
TP,  true  positive;  TN,  true  negative;  FP,  false  positive;  FN,  false  negative 
Table  1.  Clinical  Characteristics  and  Outcome  of  the  43  Patients  with  Fulminant  Hepatic  Failure
FHF,  based  on  the  interval  between  the  onset  of  jaundice  and 
encephalopathy,  were  subsequently  proposed,  and  these 
differed  with  respect  to  the  etiology,  the  risk  of  cerebral  edema 
and  the  prognosis  for  survival  with  administering  medical 
therapy  alone
2-5).  The  original  classifications  of  both  O'Grady  et 
al.
6)  and  Bernau  et  al.
2)  omitted  the  requirement  for  the  absence 
of  prior  hepatic  disease  and  the  classifications  included  those 
patients  with  FHF  syndrome  and  who  had  pre-existing 
asymptomatic  liver  diseases.
An  estimated  2000  patients  per  year  develop  FHF  in  the 
United  States
7).  Despite  the  advances  in  critical  care 
management,  medical  therapy  alone  has  resulted  in  overall 
survival  rates  of  only  10～40%  for  patients  suffering  with  FHF 
and  who  progress  to  stage  III  or  IV  hepatic  encephalopathy
7). 
Liver  transplantation  (LT)  represents  the  only  lifesaving  therapy 
for  patients  with  progressive  FHF  and  this  has  increased  the 
survival  rates  to  60～80%
8, 9). 
Distinguishing  the  patients  with  FHF  who  require  LT  from 
those  patients  who  will  likely  survive  with  intensive  medical  care 
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to  a  critical  shortage  of  donor  livers.  Although  two  prognostic 
scoring  systems,  referred  to  as  the  London
10, 11)  and  Clichy
12-15) 
criteria,  have  been  used  to  assess  European  patients  with  FHF, 
only  one  transplant  center  in  the  U.S.A.
16)  has  assessed  the 
applicability  of  the  London  scoring  system.  The  aim  of  the 
present  study  was  to  compare  the  sensitivity,  specificity,  the 
positive  and  negative  predictive  power  and  the  predictive 
accuracy  of  both  the  London  and  Clichy  prognostic  scores  for 
patients  with  FHF. 
MATERIALS AND METHODS
Patients
Between  June  1990  and  April  1999,  94  patients  with  FHF 
were  admitted  to  the  Liver  Support  Unit  of  Cedars-Sinai  Medical 
Center  for  diagnosis  and  treatment.  Both  the  London  and  Clichy 
prognostic  scoring  systems  were  used  to  access  43  patients  on 
admission.  The  other  51  patients  were  ineligible  because  they 
had  received  transfusions  of  fresh  frozen  plasma  prior  to 
admission  or  that  the  measurement  of  factor  V  activity  with 
using  the  available  frozen  serum  would  have  yielded  unreliable 
results
17).
The  clinical  characteristics  and  outcomes  of  the  43  patients 
are  summarized  in  Table  1.  The  mean  age  of  the  43  patients 
(28  females  and  15  males)  was  37  years  (range:  10  to  75 
years).  Acetaminophen  (ACM)  toxicity  was  the  etiology  of  FHF 
for  16  of  43  patients  (37%).  Non-acetaminophen  (NACM) 
etiologies  were  identified  for  27  patients  (63%):  they  were 
indeterminate  (n=11),  other  hepatotoxic  drugs  (n=5),  hepatitis  B 
(n=3);  hepatitis  A  (n=2),  ischemia  (n=2),  heat  stroke  (n=1), 
autoimmune  hepatitis  (n=1),  Wilson's  disease  (n=1),  hemolysis, 
elevated  liver  enzymes  and  low  platelet  (HELLP)  syndrome 
(n=1). 
At  the  time  of  transfer  to  our  hospital,  8  of  16  (50%)  patients 
with  ACM  toxicity  and  who  had  grade  III  or  IV  hepatic 
encephalopathy  were  intubated  or  they  required  urgent 
intubation  upon  admission.  Among  the  27  patients  with  NACM 
etiologies  of  FHF,  23  (85%)  were  admitted  with  grade  III  or  IV 
hepatic  encephalopathy.  All  the  patients  were  treated  in  a 
specialized  intensive  care  unit  by  a  multidisciplinary  team  of 
hepatologists,  transplant  surgeons,  intensive  care  specialists  and 
consultants.  Eighteen  patients  (8  with  ACM  and  10  with  NACM 
etiologies),  underwent  one  or  more  treatments  with  experimental 
bioartificial  liver  (BAL)  support  (Table  1)  under  a  protocol  that  as 
been  previously  described
18, 19).
Prognostic  Scoring
The  static  and  dynamic  information  required  for  evaluating 
both  the  London  and  Clichy  criteria  were  compared  on 
admission.  The  London  prognostic  criteria  that  were  specific  for 
patients  with  the  ACM  and  NACM  etiologies  of  FHF  were 
used
10).  The  specific  criteria  for  a  poor  prognosis  for  the  patients 
with  ACM-induced  FHF  included:  1)  an  arterial  blood  pH  <7.30 
regardless  of  the  stage  of  hepatic  encephalopathy  or  2)  the 
constellation  of  grade  III  or  IV  hepatic  encephalopathy  with  a  PT 
of  >100  sec.  (which  corresponds  in  our  laboratory  to  a  PT  INR 
of  >6.5)  and  a  serum  creatinine  level  >3.4  mg/dL.  The  adverse 
prognostic  criteria  for  the  patients  with  the  NACM  etiologies  of 
FHF  in  the  London  scoring  system
10),  which  are  independent  of 
the  stage  of  hepatic  encephalopathy,  included:  1)  a  PT  INR  >6.5 
or  2)  at  least  3  of  the  5  following  indicators:  a)  age  <10  or  >40 
years;  b)  indeterminate,  halothane  or  non-acetaminophen  drug 
etiologies;  c)  the  interval  between  jaundice  and  the  onset  of 
hepatic  encephalopathy  >7  days;  d)  a  PT  INR  >3.5;  or  e)  a 
serum  bilirubin  level  >17.5  mg/dL. 
The  Clichy  criteria  included  the  stages  I-IV  hepatic 
encephalopathy  and  a  factor  V  activity  of  <20%  in  the  patients 
<30  years  of  age  or  <30%  in  the  patients  >30  years  of  age
15). 
The  factor  V  activity  was  measured  in  the  serum  obtained  on 
admission  by  the  Cedars-Sinai  clinical  laboratory  with  using  a 
standard  one-stage  clotting  technique.  Frozen  plasma  was  not 
used  to  avoid  underestimation  of  the  true  factor  V  activity
17). 
Patients  were  also  excluded  if  they  had  received  a  fresh  frozen 
plasma  transfusion  prior  to  admission.
Data  Analysis 
The  sensitivity,  specificity,  positive  predictive  value,  negative 
predictive  value  and  accuracy  were  calculated  to  compare  the 
predictive  value  of  the  London  and  Clichy  criteria
20).  A  true 
positive  outcome  was  defined  as  a  patient  who  met  the  criteria 
for  LT  and  who  either  died  with  recieving  medical  therapy  or 
they  underwent  LT.  A  true  negative  outcome  was  defined  as  a 
patient  who  didn't  meet  the  criteria  for  LT  and  who  survived 
with  receiving  medical  therapy  alone.  Sensitivity  was  defined  as 
the  number  of  true  positive  outcomes  divided  by  the  total  number 
of  patients  who  died  or  underwent  LT.  Specificity  was  calculated 
as  the  number  of  true  negative  outcomes  divided  by  the  total 
number  of  patients  who  survived  without  LT.  The  positive 
predictive  value  (PPV)  was  defined  as  the  ratio  of  the  true 
positives  to  the  combined  true  and  false  positives.  The  negative 
predictive  value  (NPV)  was  defined  as  the  ratio  of  true  negatives 
to  the  combined  true  and  false  negatives.  The  predictive  accuracy 
(PA)  was  defined  as  the  ratio  of  the  combined  true  positives  and 
negatives  to  the  total  number  of  patients. 
RESULTS
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Medical  Therapy LT
Acetaminophen  (N=16) 
Non-Acetaminophen  (N=27)
Combined  (N=43)
75%  (9/12)
22%  (2/9)
52%  (11/21)
75%  (3/4)
89%  (16/18)
86%  (19/22)
LT,  liver  transplantation. 
Table  2.   Survival to the Time  of Hospital  Discharge with Medical 
Therapy  or  LT
Sensitivity
* Specificity PPV NPV PA
Acetaminophen 
      London    Criteria 71%  (5/7) 78%  (7/9) 71%  (5/7) 78%  (7/9) 75%  (12/16)
Clichy  Criteria 86%  (6/7) 56%  (5/9) 60%  (6/10) 83%  (5/6) 69%  (11/16)
Non‐acetaminophen 
    London  Criteria 96%  (24/25) 100%  (2/2) 100%  (24/24) 67%  (2/3) 96%  (26/27)
Clichy  Criteria 80%  (20/25) 100%  (2/2) 100%  (20/20) 29%  (2/7) 82%  (22/27)
Total 
London  criteria 91%  (29/32) 82%  (9/11) 94%  (29/31) 75%  (9/12) 89%  (38/43)
Clichy  criteria 81%  (26/32) 64%  (7/11) 87%  (26/30) 54%  (7/13) 77%  (33/43)
PPV,  positive  predictive  value;  NPV,  negative  predictive  value;  PA,  predictive  accuracy.
Table  3.  Comparison  of  the  London  and  Clichy  Criteria  for  the  43  Patients  with  Fulminant  Hepatic  Failure
43  patients.  Eleven  of  the  43  patients  (26%)  survived  with 
receiving  medical  therapy  alone.  The  survivors  included  9  of  16 
(56%)  patients  with  ACM  etiologies  and  2  of  27  (7%)  patients 
with  NACM  etiologies.  Among  the  survivors  who  received 
medical  therapy  alone,  5  of  the  9  patients  (56%)  in  the  ACM 
group  and  0  of  2  in  the  NACM  group  had  been  treated  with 
BAL  support.  Ten  of  43  patients  (23%)  died  during  medical 
therapy,  including  3  of  16  (19%)  in  the  ACM  group  and  7  of  27 
(26%)  in  the  NACM  group.  Among  those  patients  who  died 
without  LT,  BAL  support  was  used  for  one  patient  in  the  ACM 
group  and  for  2  patients  in  the  NACM  group.  Twenty-two  of  the 
43  patients  (51%)  that  were  transplanted  included  4  of  the  16 
patients  (25%)  with  ACM  etiologies  and  18  of  the  27  patients 
(67%)  with  NACM  etiologies.  Nineteen  of  the  22  transplanted 
patients  (3  ACM  and  16  NACM)  survived  to  discharge  (Table  2). 
Among  the  transplanted  patients  who  died,  only  one  in  the 
NACM  group  had  received  BAL  support.
Table  3  compares  the  sensitivity,  specificity,  the  positive  and 
negative  predictive  values  and  the  predictive  accuracy  of  the 
London  and  Clichy  prognostic  scoring  systems  at  the  time  of 
admission.  In  the  ACM  group,  the  sensitivity  (the  proportion  of 
patients  fulfilling  the  criteria  who  died)  was  superior  for  the 
Clichy  criteria  (86%  vs.  71%,  respectively),  while  the  specificity 
(the  proportion  of  patients  surviving  who  did  not  fulfill  criteria) 
was  better  for  the  London  criteria  (78%  vs.  56%,  respectively). 
The  PPV,  NPV  and  PA  of  both  criteria  were  low  and  of 
marginal  benefit  in  assessing  the  prognosis.
Analysis  of  the  specific  elements  of  the  London  criteria  for 
the  ACM  hepatotoxicity  (Table  4)  showed  that  the  PPV  and  PA 
of  metabolic  acidosis  with  an  arterial  pH  <7.30  were  100%  and 
87%,  respectively.  In  contrast,  the  PPV  and  PA  for  the 
combination  of  all  3  variables  in  the  ACM  group  was  0%  and 
47%,  respectively.  The  NPVs  for  either  an  arterial  pH  <7.30  or 
all  3  variables  were  78%  and  47%,  respectively. 
For  the  patients  with  NACM  etiologies  of  FHF  (Table  3),  the 
overall  London  criteria  were  superior  to  those  of  the  Clichy 
criteria:  sensitivity  (96%  vs  80%,  respectively),  specificity  (100% 
vs  100%,  respectively),  PPV  (100%  vs  100%,  respectively),  NPV 
67%  vs  29%,  respectively)  and  PA  (96%  vs  82%,  respectively). 
As  shown  in  Table  4,  which  assesses  the  individual  scored 
elements  of  the  London  criteria,  the  PPV  and  PA  of  a  PT  INR 
of  >6.5  were  100%  and  57%,  respectively.  In  contrast,  the 
presence  of  =3  of  the  5  prognostic  variables  had  a  similar  PPV 
(100%),  but  a  higher  PA  (93%)  for  the  need  for  LT  in  our 
patients.  However,  the  NPV  for  a  PT  INR  >6.5  or  =3  of  the  5 
prognostic  variables  in  the  NACM  group  were  only  14%  and 
50%,  respectively. 
DISCUSSION
Distinguishing  the  patients  with  FHF  who  will  require  urgent 
LT  from  those  who  will  likely  to  recover  with  medical  therapy 
alone  remains  problematic.  Recognizing  the  subset  of  patients 
who  require  LT  is  critically  important  because  the  rapid 
progression  of  FHF  requires  immediate  treatment  since  death  or 
the  development  of  absolute  contraindications  for  LT  often 
occurs  before  a  donor  organ  becomes  available.  In  view  of  the 
severe  shortage  of  donor  organs  and  the  previous  reports  that 
up  to  60%  of  patients  with  FHF  due  to  etiologies  such  as  ACM 
and  viral  hepatitis  may  recover  without  LT
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PPV NPV PA
Acetaminophen 
    Arterial  PH<7.3 100% 78% 87%
    All  3  of  3  variables     0% 47% 47%
Non‐acetaminophen 
    PT  INR  >6.5 100% 14% 57%
    Any  3  of  5  variables 100% 50% 93%
PPV,  positive  predictive  value;  NPV,  negative  predictive  value;  PA,  predictive  accuracy.
Table  4.    Validation  of  Specific  Elements  of  the  London  Criteria  for  the  43  FHF  Patients 
imperative  to  avoid  unnecessary  LT  for  the  patients  who  will 
recover  with  receiving  medical  therapy  alone.  The  urgency  of 
establishing  an  accurate  prognosis  is  accentuated  by  the  fact 
that  FHF  patients  in  the  U.S.  are  often  cared  for  at  hospitals  for 
several  days  before  being  transferred  to  a  transplant  center
11, 16). 
The  severity  of  FHF  at  the  time  of  admission  to  our  center  may 
be  partly  explained  by  the  median  4.4  days  before  transfer, 
which  is  similar  to  the  median  of  4  days  reported  by  the 
University  of  Pittsburgh
16).
The  London  and  Clichy  prognostic  criteria  are  the  most 
frequently  used  systems  to  determine  the  probability  of  survival 
without  LT  for  patients  with  FHF.  The  London  criteria  were 
developed  by  retrospectively  identifying  the  most  discriminatory 
combination  of  prognostic  variables  via  stepwise  logistic 
regression  analysis  of  588  patients  who  suffered  with  ALF  and 
who  were  treated  medically  between  1973  and  1985
10).  The 
accuracy  of  the  London  criteria  was  further  assessed  by 
retrospective  analysis  of  another  175  patients  (121  ACM  and  54 
NACM  etiologies)  who  were  treated  during  1986-87.  The 
specific  criteria  for  the  ACM  and  NACM  etiologies  were  selected 
based  on  the  probability  of  survival  (5%)  with  receiving  medical 
therapy  alone.  Although  the  grade  of  hepatic  encephalopathy 
was  a  prognostic  indicator  for  FHF  due  to  ACM  etiologies,  it 
was  not  for  the  NACM  etiologies.  The  Clichy  prognostic  criteria 
were  validated  in  a  series  of  90  patients  who  suffered  with  with 
FHF  due  to  acute  viral  hepatitis  (primarily  hepatitis  B)  and  who 
had  factor  V  activities  <50%  of  normal
12).  Among  the  43  patients 
with  stage  III-IV  hepatic  encephalopathy  who  met  these  criteria, 
factor  V  activities  <20%  for  the  patients  <30  years  of  age  or 
<30%  for  the  patients  >30  years  of  age  were  associated  with 
survivals  of  10%  with  receiving  medical  therapy  alone  and  84% 
with  LT.  The  PPV  and  NPV  for  death  with  medical  therapy 
alone  were  82%  and  98%,  respectively.  Application  of  these 
criteria  identified  95%  of  the  survivors.  Currently,  the  Clichy 
prognostic  criteria  are  exclusively  used  by  some  centers  for  all 
patients  with  FHF,  regardless  of  the  etiology
15).
The  London  and  Clichy  prognostic  criteria  have  not  been 
previously  compared  in  American  patients  with  FHF  that's  due 
to  both  the  ACM  and  NACM  etiologies.  Several  sources  of 
potential  bias  must  be  considered  when  comparing  our  results 
with  those  of  the  other  previous  reports.  Although  all  43  patients 
received  standard  intensive  care  from  a  multidisciplinary  team, 
they  were  also  eligible  for  experimental  BAL  support  under  the 
protocol
18, 19).  Indeed,  8  patients  with  ACM  etiologies  and  10  with 
NACM  etiologies  underwent  BAL  support  (Table  1).  Comparing 
the  prognostic  scoring  systems  only  at  the  time  of  admission, 
rather  than  serially,  might  have  theoretically  underestimated  the 
prognostic  power  of  either  system.  Although  we  intended  to 
enroll  consecutive  patients  admitted  with  FHF,  it  was  necessary 
to  exclude  those  patients  who  had  received  fresh  frozen  plasma 
before  admission  or  they  only  had  a  frozen  blood  specimen  that 
would  have  underestimated  the  factor  V  activity.  Despite  this 
potential  selection  bias,  the  etiologies  of  FHF  in  our  43  patients 
and  the  proportions  of  patients  with  specific  FHF  etiologies  were 
quite  similar  to  those  reported  for  295  consecutive  American 
patients  with  FHF  from  13  U.S.  centers
25).  Inclusion  of  patients 
undergoing  transplantation  (25%  of  the  ACM  group  and  67%  of 
the  NACM  group,  respectively)  as  true  positives  also  introduces 
a  potential  bias  that's  common  to  many  reported  series
15, 16), 
since  it  cannot  be  proved  that  every  patient  undergoing  LT 
would  have  died  with  receiving  only  continued  medical  therapy. 
In  this  regard,  it  is  important  to  note  that  every  patient  who  died 
during  medical  therapy  met  the  London  and/or  Clichy  criteria  for 
a  survival  prognosis  of  =5%  without  LT. 
For  our  16  patients  with  FHF  due  to  ACM  toxicity  (Table  3), 
theeir  overall  PPV  and  PA  of  the  London  criteria  (71%  and  75%, 
respectively)  were  superior  to  those  of  the  Clichy  criteria  (60% 
and  69%,  respectively).  Although  the  PPV  (the  proportion  of 
patients  fulfilling  criteria  who  died)  of  the  London  criteria  (71%) 
was  greater  than  that  of  the  Clichy  criteria  (60%),  neither  the 
PPV  nor  the  NPV  (the  proportion  of  patients  not  fulfilling  the 
criteria  who  survived)  of  the  London  criteria  were  as  high  as 
those  of  the  several  previously  published  studies
9, 27-29).  The 
PPV  (71%)  and  PA  (75%)  of  the  London  criteria  of  our  patients 
were  inferior  to  the  PPV  of  84%  and  the  PA  of  85%  as  originally 
reported  by  O'Grady  et  al.
10),  but  they  were  in  close  agreement 
with  the  PPV  of  73%  and  the  PA  of  72%  as  reported  by  Anand 
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29).  In  contrast,  our  sensitivity,  specificity,  PPV  and  PA 
were  comparable  or  greater  than  the  values  reported  by  Izumi 
et  al.
31)  for  81  patients  with  ACM-induced  FHF.  Specifically,  the 
PPV  of  the  Clichy  criteria  in  our  study  (60%)  was  in  close 
agreement  with  the  57%  reported  by  Izumi  et  al.
30)  for  81  ACM 
patients  who  were  not  transplanted  and  they  had  a  factor  V 
activity  of  <10%,  regardless  of  the  grade  of  hepatic 
encephalopathy.  The  PPV  of  49%  reported  by  Izumi  et  al.
30)  for 
factor  V  levels  <20%  was  lower  than  our  PPV  with  using 
age-adjusted  criteria.  Although  their  PPV  of  a  factor  V  level 
<20%  for  the  subgroup  of  ACM  patients  with  stage  III-IV 
hepatic  encephalopathy  increased  to  73%,  it  remained  inferior  to 
the  PPV  of  92%  for  the  London  criteria.  However,  it  is  important 
to  note  that  among  the  110  FHF  patients  reported  on  by  Izumi 
et  al  (88  ACM  etiologies  and  22  NACM  etiologies)  the  admission 
levels  of  factor  V  were  significantly  lower  in  the  49  patients  who 
died  (median:  5%,  range:  1～27%)  than  in  the  61  patients  who 
survived  (median:  10%,  range:  2～70%)
30). 
The  most  accurate  predictor  of  death  without  LT  among  our 
ACM  patients  was  an  arterial  pH  <7.30  on  admission.  Whereas 
an  arterial  pH  <7.30  had  a  high  PPV,  NPV  and  PA  in  both  our 
study  and  the  study  of  O'Grady  et  al.
10),  Anand  et  al.
29)  and 
Shakil  et  al.
16)  reported  much  lower  values. 
Conversely,  the  PPV,  NPV  and  PA  of  the  other  3  variables 
for  our  patients  were  substantially  lower  than  the  values 
reported  in  the  three  other  previous  series
10, 16, 29)  .  A  major 
confounding  factor  is  the  likelihood  that  BAL  support  contributed 
to  the  survival  of  more  patients  with  ACM  toxicity  in  our  series 
than  was  predicted  by  the  London  criteria.  Grade  III  or  IV 
encephalopathy  is  more  common  in  the  non-ACM  group  (85%) 
than  that  in  the  ACM  group  (50%),  and  this  may  be  a  risk  factor 
for  a  poor  outcome  in  those  groups
31),  yet  BAL  is  known  as  a 
more  effective  treatment  for  hepatic  encephalopathy  than  for 
other  impaired  hepatic  functions
32, 33).  This  speculation  is 
supported  by  the  results  of  a  randomized,  controlled  trial  of  BAL 
for  treating  FHF  that's  due  to  ACM  toxicity,  and  the  results 
showed  a  significantly  increased  survival  compared  to  standard 
intensive  care
32).  Demetriau  et  al.  reported  that  ALF  patients 
with  known  etiologies  such  as  virus,  ACM,  other  drugs  or 
chemical  toxicities  have  a  better  prognosis,  and  ACM-FHF  can 
be  associated  with  a  high  spontaneous  recovery  rate;  however, 
a  few  patients  suffering  withsevere  variants  of  ACM-FHF  can 
rapidly  progress  to  cerebral  edema  and  death
33).  Further  studies 
with  a  large  number  of  patients  are  needed  to  identify  these 
additional  prognostic  variables.
In  our  27  patients  with  NACM  etiologies  for  FHF,  the  overall 
PPV  of  both  the  London  and  Clichy  prognostic  criteria  was 
100%,  while  the  PA  was  96%  and  82%,  respectively  (Table  3). 
Our  results  with  the  Clichy  criteria  compared  favorably  to  the 
prospective  results  at  admission  to  the  hospital  of  Izumi  et  al.
30) 
who  reported  a  PPV  of  85%  for  a  factor  V  level  <20%  and 
100%  for  a  factor  V  level  <10%  in  17  of  22  NACM  patients  with 
grade  I-IV  hepatic  encephalopathy  and  who  were  not 
transplanted.  For  those  patients  with  grade  III  or  IV 
encephalopathy,  the  PPV  was  91%  for  a  factor  V  level  <20%. 
The  overall  PPV  and  PA  of  the  London  criteria  for  the  17 
patients  reported  by  Izumi  et  al.
30)  were  93%  and  88%, 
respectively,  compared  to  100%  and  96%,  respectively,  for  our 
patients.  Pauwels  et  al.  retrospectively  compared  both 
prognostic  scoring  systems  for  81  French  adults  with  NACM 
FHF  and  who  were  treated  with  medical  therapy  alone  on 
admission  and  then  again  at  48,  24  and  <24  h  before  death
24). 
The  mortality  with  medical  therapy  alone  was  81%.  On 
admission,  the  PPV  of  the  London  and  Clichy  criteria  was  96% 
and  90%,  respectively,  while  the  PA  was  80%  vs.  60% 
respectively.  The  PPV  did  not  increase  when  it  was  reassessed 
48,  24  or  <24  h  before  death  for  either  London  or  Clichy  criteria, 
but  the  PA  predictably  increased  as  death  became  imminent.  In 
contrast  to  our  results  and  those  of  others  for  the  PPVs  and 
PAs  of  the  NACM  etiologies  of  FHF,  Anand  et  al.  reported  an 
overall  PPV  and  PA  of  only  68%  and  61%,  respectively,  for  145 
patients  who  were  treated  in  the  U.K.
29).  Unfortunately,  the 
overall  PPV  was  not  reported  by  Shakil  et  al.
16),  although  they 
found  acceptable  PPVs  and  PAs  for  the  individual  components 
of  the  London  criteria  in  144  American  patients  who  were 
treated  for  FHF  due  to  NACM  etiologies;  these  patients  were 
treated  between  1982-95  at  the  University  of  Pittsburgh.  The 
results  in  non-transplanted  patients  with  FHF  reported  by  Izumi 
et  al.
30)  and  Pauwels  et  al.
24)  indicate  that  the  potential  bias  of 
including  transplanted  patients  as  true  positives  in  our  study 
may  have  caused  only  a  modest  increase  in  the  PPV  and  PA. 
While  our  PPV  of  a  PT  INR  >6.5  was  comparable  to  those 
of  all  the  other  previous  reports
10, 16, 29),  the  PPV  and  PA  of  =3 
of  the  5  prognostic  variables  in  our  study  were  similar  to  those 
of  O'Grady  et  al.
10)  but  they  were  appreciably  higher  than  those 
of  Anand  et  al.
29)  and  Shakil  et  al.
16)  The  overall  PPV  (100%) 
and  PA  (96%)  for  the  combination  of  the  two  scored  elements 
were  similar  to  the  results  of  O'Grady  et  al.
10)  but  they  exceeded 
those  reported  by  others
24-29).  Our  PPV  and  PA  of  the  Clichy 
criteria  for  patients  with  NACM  etiologies  were  100%  and  82%, 
respectively.  These  results  were  slightly  greater  than  those 
previously  reported  by  others
24-30). 
Our  overall  NPV  was  67%  for  the  London  criteria  for  patients 
suffering  with  the  NACM  etiologies  of  FHF,  while  the  values 
reported  by  others  ranged  from  25%  to  82%.  In  contrast,  the 
NPV  for  the  Clichy  criteria  was  only  29%,  which  was  nearly 
identical  to  the  NPV  of  28%  on  admission  in  the  study  of 
Pauwels  et  al.  on  non-transplanted  patients
24).  The  fact  that  our 
PPVs  were  greater  than  the  sensitivities  (the  proportion  of 
fatalities  meeting  the  criteria),  while  our  specificities  (the Won-Choong  Choi,  et  al  :  Comparison  of  the  Applicability  of  Two  Prognostic  Scoring  Systems  in  Patients  with  Fulminant  Hepatic  Failure 99
proportion  of  survivors  not  meeting  the  prognostic  criteria)  were 
much  greater  than  our  NPVs  (Table  3),  indicates  there  was 
excessive  mortality  for  the  patients  suffering  with  NACM  FHF 
and  who  did  not  fulfill  the  criteria  at  the  time  of  admission  for 
death  without  LT.
To  conclude,,  overall,  the  London  criteria  more  accurately 
predicted  the  need  for  transplantation,  but  neither  the  London 
nor  Clichy  prognostic  criteria  accurately  predicted  the  outcome 
of  our  patients  with  FHF  due  to  ACM.  The  positive  impact  of 
BAL  support  on  our  ACM  patients  may  have  contributed  to  the 
survival  without  LT,  which  exceeded  the  predictions  of  both 
prognostic  systems
33).  In  contrast,  both  the  London  and  Clichy 
prognostic  criteria  exhibited  high  PPVs  for  survival,  but  the  PA 
of  the  London  criteria  was  superior.  Additional  multicenter 
studies  should  be  conducted  to  refine  these  prognostic  scoring 
systems  so  physicians  can  rapidly  identify  the  patients  suffering 
with  either  the  ACM  or  NACM  etiologies  of  FHF,  and  who  will 
survive  without  undergoing  liver  transplantation.
Abbreviations
FHF,  fulminant  hepatic  failure;  LT,  liver  transplantation;  ACM, 
acetaminophen;  NACM,  non-acetaminophen;  PPV,  positive 
predictive  value;  NPV,  negative  predictive  value;  PA,  predictive 
accuracy.
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